Effective prolonged suppression of HIV-1 viral load using tenofovir alafenamide, emtricitabine and efavirenz in an adult with BMI >59 kg/m2
- 18 August 2023
- journal article
- research article
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 34 (14) , 1072-1074
Abstract
Limited information is available regarding the efficacy of antiretrovirals in people with HIV-1 and high or very high Body Mass Index (BMI). This is especially the case for the alafenamide salt of tenofovir as clinical trials have only enrolled patients with BMI ≤30 kg/m2. Lower concentrations of some antiretrovirals are expected in patients with BMI >30 kg/m2 due to potential changes in clearance and distribution of medication. This report describes an individual taking tenofovir alafenamide, emtricitabine and efavirenz in whom HIV-1 viral load was consistently undetectable (2. Further data is required to support the efficacy of antiretrovirals in individuals with high and very high BMI.Keywords
This publication has 16 references indexed in Scilit:
- Drug dosing in obese adultsAustralian Prescriber, 2017
- Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialThe Lancet Gastroenterology & Hepatology, 2016
- Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and CanadaAIDS Research and Human Retroviruses, 2016
- Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adultsAIDS, 2015
- Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trialThe Lancet, 2014
- Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive AdultsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
- Efavirenz Pharmacokinetics in Cerebrospinal Fluid and Plasma over a 24-Hour Dosing IntervalAntimicrobial Agents and Chemotherapy, 2012
- Increasing Rates of Obesity among HIV-Infected Persons during the HIV EpidemicPLOS ONE, 2010
- Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and Other Tenofovir Phosphonoamidate Prodrugs by Human ProteasesMolecular Pharmacology, 2008
- Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infectionClinical Pharmacology & Therapeutics, 2003